marburg
ebola
virus
caus
sever
hemorrhag
fever
human
nonhuman
primat
current
effect
treatment
licens
vaccin
although
number
vaccin
platform
proven
success
anim
model
ideal
filoviru
vaccin
candid
abl
provid
rapid
protect
follow
singl
immun
potenti
work
postexposur
crossreact
multival
marburg
viru
strain
relev
ebola
viru
speci
strain
current
multipl
platform
provid
prophylact
protect
nonhuman
primat
includ
dna
recombin
adenoviru
serotyp
recombin
human
parainfluenza
viru
viruslik
particl
addit
singl
platform
recombin
vesicular
stomat
viru
demonstr
prophylact
postexposur
protect
nonhuman
primat
result
demonstr
achiev
vaccin
protect
filovirus
possibl
challeng
prove
safeti
efficaci
order
obtain
vaccin
readi
human
use
respons
lymphopenia
characterist
individu
surviv
infect
base
serolog
crossreact
genet
analys
five
speci
ebov
zair
ebolaviru
zebov
sudan
ebolaviru
sebov
cote
divoir
ebolaviru
ciebov
reston
ebolaviru
rebov
bundibugyo
ebolaviru
bebov
recent
identifi
propos
separ
speci
isol
uganda
contrast
marv
contain
singl
speci
lake
victoria
marburgviru
see
figur
geograph
locat
filoviru
outbreak
rebov
speci
ebov
appear
tropic
africa
identifi
multipl
time
cynomolgu
macaqu
import
philippin
identifi
high
incid
pig
mortal
philippin
virul
monkey
rebov
appar
pathogen
human
despit
least
case
infect
casefat
rate
date
two
report
case
ciebov
fatal
therefor
rebov
ciebov
less
concern
regard
vaccin
develop
thu
minim
filoviru
vaccin
would
protect
marv
strain
least
three
african
ebov
speci
zebov
sebov
bebov
filoviru
transmiss
typic
due
direct
contact
blood
secret
tissu
infect
patient
anim
eg
gorilla
chimpanze
figur
analysi
clinic
specimen
found
evid
viru
saliva
stool
semen
breast
milk
tear
blood
well
nasal
skin
swab
mucos
exposur
also
demonstr
rout
infect
experiment
expos
nonhuman
primat
addit
unconfirm
data
suggest
airborn
rout
mode
transmiss
limit
number
human
case
current
data
point
toward
number
fruit
bat
speci
reservoir
ebov
marv
figur
suggest
sporad
outbreak
virus
continu
vector
control
viabl
option
number
laboratoryacquir
infect
document
sinc
first
filoviru
incid
peopl
seven
die
develop
would
name
marburg
hemorrhag
fever
follow
handl
african
green
monkey
tissu
germani
former
yugoslavia
two
laboratoryacquir
marv
infect
one
fatal
report
russia
four
known
highrisk
laboratori
exposur
ebov
report
first
occur
uk
sebov
follow
treatment
human
interferon
ifn
human
convalesc
plasma
individu
surviv
two
separ
incid
accident
needl
stick
occur
work
anim
one
usa
mouseadapt
zebov
person
appear
infect
one
russia
guinea
pigadapt
zebov
infect
individu
surviv
recent
needl
stick
incid
occur
infect
anim
zebov
germani
uncertain
whether
individu
actual
infect
howev
follow
postexposur
vaccin
liveattenu
recombin
vesicular
stomat
viru
rvsv
base
vaccin
express
zebov
glycoprotein
gp
individu
exhibit
sign
ebola
hemorrhag
fever
ehf
absenc
effect
treatment
vaccin
remain
best
option
protect
laboratori
staff
sporad
geograph
divers
occurr
filoviru
outbreak
make
difficult
select
target
popul
vaccin
also
caus
consider
difficulti
establish
tradit
clinic
trial
consid
fact
endem
zone
marv
ebov
overlap
singl
vaccin
would
ideal
multipl
approach
yield
promis
result
prophylact
vaccin
proven
highli
efficaci
nonhuman
primat
studi
rvsv
proven
work
prophylact
vaccin
postexposur
treatment
logist
distribut
vaccin
requir
multipl
immun
central
africa
difficult
would
prefer
prophylact
vaccin
efficaci
follow
singl
immun
filoviru
vaccin
platform
almost
alway
initi
test
mous
model
ebov
success
progress
guinea
pig
model
start
model
marv
suitabl
mous
model
avail
final
nonhuman
primat
date
small
anim
model
serv
good
predictor
success
nonhuman
primat
model
thu
platform
exhibit
extrem
high
success
small
anim
model
progress
nonhuman
primat
current
rvsv
recombin
adenoviru
serotyp
without
dna
prime
vaccin
platform
undergon
extens
vari
multipl
antigen
multival
vaccin
crossprotect
studi
test
nonhuman
primat
consist
demonstr
protect
number
platform
exist
eg
dna
recombin
adenoviru
rad
platform
recombin
human
parainfluenza
viru
viruslik
particl
vlp
review
either
proven
efficaci
test
extens
nonhuman
primat
circumst
prevent
tradit
drug
andor
vaccin
test
perform
us
fda
allow
use
anim
rule
wherebi
laboratori
anim
data
use
demonstr
vaccin
efficaci
place
human
trial
vaccin
marv
ebov
virus
abil
use
regul
would
greatli
speed
possibl
obtain
avail
vaccin
howev
requir
immun
correl
protect
defin
nonhuman
primat
filoviru
anim
model
mous
guinea
pig
hamster
either
fulli
recapitul
diseas
requir
adapt
virus
produc
similar
diseas
characterist
unfortun
immun
correl
protect
filovirus
well
defin
vaccin
platform
discuss
dnarad
rad
alon
vlp
rvsvbase
report
product
virusspecif
igg
antibodi
correl
protect
survivor
furthermor
vaccin
result
surviv
follow
challeng
success
induc
antibodi
respons
pathophysiolog
clinic
symptom
ebov
marv
infect
accur
repres
nonhuman
primat
model
model
meet
requir
anim
rule
nearcomplet
surviv
predict
certain
igg
titer
produc
vaccin
platform
suggest
specif
threshold
igg
titer
may
use
correl
protect
current
unclear
whether
antibodi
alon
suffici
protect
passiv
transfer
immun
serum
naiv
nonhuman
primat
protect
howev
recent
report
purifi
convalesc
igg
success
protect
rhesu
macaqu
marv
challeng
rodent
model
passiv
transfer
suffici
protect
adopt
transfer
knockout
model
suggest
b
cell
mediat
protect
immun
may
also
like
nonhuman
primat
model
deplet
tcell
subset
indic
cell
requir
viru
clearanc
despit
appar
requir
cell
respons
either
low
inconsist
limit
data
suggest
igg
titer
also
correl
surviv
infect
human
addit
specif
hla
class
b
allel
tcell
activ
measur
product
specif
cytokin
thu
gpspecif
igg
titer
correl
surviv
follow
experiment
infect
nonhuman
primat
howev
clear
antigenspecif
tcell
respons
also
elicit
probabl
involv
viral
clearanc
protect
although
mechan
protect
remain
undefin
clarif
immun
correl
protect
lead
vaccin
platform
would
open
door
rapid
develop
vaccin
recipi
could
test
ensur
vaccin
elicit
desir
predict
protect
respons
follow
vaccin
replicationcompet
vaccin
number
advantag
nonrepl
vaccin
includ
induct
durabl
longerlast
immun
typic
requir
fewer
immun
confer
protect
effect
mani
vectorbas
vaccin
may
compromis
preexist
immun
eg
seroposit
mani
case
method
overcom
alter
vector
background
ad
mucos
deliveri
vesicular
stomat
viru
vsv
gener
popul
low
rate
exposur
moreov
individu
seroposit
gener
immun
respons
direct
toward
neutral
vsv
g
present
vaccin
vector
modifi
vector
wherebi
major
surfac
protein
fusion
protein
f
hemagglutinin
hn
replac
exclus
zebov
gp
also
exploit
method
avoid
preexist
immun
addit
abil
replic
postvaccin
result
smaller
number
particl
requir
vaccin
vesicular
stomat
viru
member
rhabdovirida
famili
develop
attenu
replicationcompet
recombin
vaccin
platform
rvsv
number
pathogen
includ
hiv
hepat
b
viru
influenza
sar
coronaviru
respiratori
syncyti
viru
human
papillomaviru
hpv
hpvassoci
cancer
revers
genet
use
replac
nativ
vsv
g
glycoprotein
either
zebov
sebov
marv
gener
viru
particl
appear
morpholog
similar
vsv
particl
contain
either
zebov
gp
sebov
gp
marv
gp
surfac
initi
studi
rvsvmarv
gp
rvsvzebov
gp
demonstr
protect
homolog
challeng
cynomolgu
macaqu
follow
singl
intramuscular
immun
anim
vaccin
rvsvzebov
gp
surviv
challeng
backchalleng
sebov
develop
clinic
symptom
one
four
surviv
survivor
may
attribut
sebov
model
result
lethal
anim
vaccin
rvsvmarv
gp
strain
musok
backchalleng
differ
marv
strain
popp
surviv
without
appar
ill
anim
vaccin
rvsvmarv
gp
subsequ
challeng
zebov
protect
similarli
anim
vaccin
rvsvzebov
gp
subsequ
challeng
marv
protect
togeth
data
suggest
within
filoviru
speci
eg
marv
crossprotect
differ
strain
crossprotect
speci
genera
eg
marv
zebov
zebov
sebov
crossprotect
heterolog
marv
strain
also
demonstr
cynomolgu
macaqu
protect
challeng
strain
ravn
diverg
marv
isol
angola
virul
marv
isol
date
vaccin
day
prior
rvsvmarv
gp
strain
musok
rvsvzebov
gp
rvsvmarv
gp
vaccin
abl
protect
cynomolgu
macaqu
homolog
aerosol
challeng
zebov
marv
respect
multipl
rout
immun
rvsv
also
demonstr
effect
deliv
rvsvzebov
gp
vaccin
oral
intranas
intramuscular
rout
day
prior
challeng
protect
cynomolgu
macaqu
subsequ
zebov
challeng
intranas
rout
appear
elicit
highest
antibodi
titer
follow
oral
intramuscular
rout
similar
studi
level
neutral
antibodi
low
rout
immun
support
hypothesi
sole
critic
protect
contrast
control
anim
undergo
reduct
lymphocyt
infect
vaccin
anim
either
show
stabl
small
increas
cell
typic
secondari
immun
respons
suggest
strong
cellmedi
immun
respons
induc
proofofconcept
studi
also
carri
demonstr
singleinject
blend
vaccin
contain
equal
amount
rvsvzebov
gp
rvsvsebov
gp
rvsvmarv
gp
could
protect
cynomolgu
macaqu
challeng
zebov
sebov
marv
illustr
principl
possibl
gener
panfiloviru
rvsvbase
blend
vaccin
addit
rvsvbebov
gp
blend
vaccin
would
potenti
protect
current
filoviru
speci
strain
current
import
human
health
reusabl
rvsv
platform
also
demonstr
wherebi
rhesu
macaqu
vaccin
rvsvsebov
gp
vaccin
week
later
rvsvzebov
gp
rvsvmarv
gp
anim
protect
subsequ
challeng
sebov
marv
thu
demonstr
reusabl
rvsv
vector
expos
glycoprotein
differ
vsv
g
includ
construct
neutral
antibodi
present
interfer
differ
vector
construct
howev
time
frame
vaccin
may
suffici
develop
antivector
immun
regardless
data
suggest
separ
immun
could
use
gener
immun
multipl
filovirus
despit
conveni
oneshot
blend
vaccin
would
logist
superior
rvsvvaccin
macaqu
protect
challeng
evid
ebov
marv
viremia
viru
isol
andor
revers
transcriptasepcr
chang
blood
chemistri
hematolog
indic
robust
protect
demonstr
anim
complet
protect
diseas
highli
suggest
steril
immun
follow
singl
dose
rvsv
vaccin
anim
typic
high
antimarv
ebov
igg
prior
challeng
also
low
level
neutral
antibodi
anim
howev
approxim
half
anim
neutral
antibodi
observ
platform
suggest
neutral
antibodi
correl
protect
howev
follow
challeng
anim
low
level
neutral
antibodi
current
main
critic
rvsv
platform
concern
safeti
especi
immunocompromis
individu
replic
vaccin
one
characterist
rvsv
vaccin
reinforc
concern
consist
detect
transient
lowlevel
vsv
viremia
typic
note
day
postvaccin
unexpect
replicationcompet
vaccin
suggest
potenti
vaccineinduc
morbid
exist
anim
studi
suggest
rvsv
vector
safe
rvsvzebov
gp
induc
sign
clinic
ill
sever
immunocompromis
nonobes
diabeticsever
combin
immunodefici
mice
even
given
tentim
normal
dose
moreov
advers
effect
report
varieti
immunocompet
mice
outbr
guinea
pig
strain
hartley
goat
hamster
feldmann
h
unpublish
data
howev
vaccin
mice
rvsv
vector
lethal
feldmann
h
unpublish
data
assess
toxic
rvsvhiv
vaccin
demonstr
rvsv
attenu
nonhuman
primat
suggest
would
safe
advanc
phase
clinic
trial
addit
major
virul
factor
vsv
thought
g
includ
vaccin
construct
date
macaqu
administ
replicationcompet
rvsv
vector
advers
effect
cynomolgu
three
rhesu
macaqu
vsvzebov
gp
cynomolgu
three
rhesu
macaqu
rvsvsebov
gp
cynomolgu
three
rhesu
macaqu
rvsvmarv
gp
six
cynomolgu
macaqu
rvsvlassa
gpc
recent
safeti
rvsv
vaccin
demonstr
follow
immun
simianhuman
immunodefici
viru
shiv
infect
rhesu
macaqu
rvsvzebov
gp
anim
show
evid
ill
vaccin
four
six
also
protect
subsequ
challeng
zebov
demonstr
vaccin
may
also
effect
immunocompromis
individu
anim
correl
low
count
lethal
outcom
suggest
cell
may
play
role
mediat
protect
lowlevel
vsv
viremia
detect
day
postvaccin
four
six
anim
interestingli
two
anim
signific
reduct
cell
follow
shiv
infect
highest
level
shiv
viremia
show
evid
vsv
viremia
surviv
challeng
two
surviv
anim
show
evid
ill
two
develop
fever
clinic
symptom
none
vaccin
anim
develop
igg
titer
zebov
gp
time
zebov
challeng
howev
igg
detect
follow
infect
three
anim
suggest
shortliv
lowlevel
vsv
viremia
may
import
protect
cell
play
role
protect
andor
igg
antibodi
may
import
protect
previous
thought
popul
risk
ebov
marv
infect
larg
limit
accident
laboratori
exposur
region
natur
filoviru
outbreak
occur
howev
filovirus
occur
wide
geograph
area
unpredict
difficult
determin
critic
target
popul
vaccin
campaign
event
filoviru
use
biolog
weapon
popul
could
risk
therefor
absenc
effect
treatment
postexposur
vaccin
would
ideal
treatment
option
util
rvsv
platform
postexposur
treatment
determin
studi
feldmann
colleagu
rvsvzebov
gp
administ
guinea
pig
mice
h
prior
challeng
h
postchalleng
h
postchalleng
result
surviv
guinea
pig
respect
treat
mice
surviv
guinea
pig
show
weight
loss
clinic
symptom
howev
surviv
time
death
delay
importantli
rvsvzebov
gp
also
protect
rhesu
macaqu
administ
min
follow
challeng
macaqu
develop
fever
lymphopenia
anim
progress
sever
diseas
includ
alter
clinic
chemistri
macular
rash
note
previous
rvsv
viremia
detect
day
postimmun
immun
anim
howev
correl
surviv
zebov
viremia
survivor
log
lower
nonsurvivor
survivor
develop
lowtit
igm
moder
igg
antibodi
respons
well
neutral
antibodi
titer
antibodi
respons
detect
nonsurvivor
note
anim
treat
rvsv
show
decreas
natur
killer
nk
cell
follow
challeng
instead
show
substanti
increas
postexposur
treatment
sebov
also
investig
rvsvsebov
gp
protect
rhesu
macaqu
administ
postexposur
follow
lethal
challeng
sebov
demonstr
postexposur
protect
possibl
postexposur
treatment
rvsvmarv
gp
min
h
h
follow
infect
rhesu
macaqu
marv
strain
musok
result
surviv
respect
treat
anim
gener
igm
igg
neutral
antibodi
transient
marv
viremia
detect
revers
transcriptasepcr
group
anim
surviv
show
symptom
consist
marv
infect
survivor
show
clinic
symptom
survivor
exhibit
alter
hematolog
andor
blood
paramet
surviv
anim
clear
viremia
day
littl
evid
ill
togeth
indic
postexposur
vaccin
possibl
first
use
human
plaqueform
unit
pfu
consist
dose
give
nonhuman
primat
rvsvzebov
gp
given
laboratori
worker
germani
approxim
h
follow
needl
stick
potenti
expos
person
zebov
individu
develop
fever
headach
myalgia
follow
vaccin
howev
symptom
manag
analges
antipyret
addit
advers
effect
report
individu
becom
ill
either
ehf
vsvassoci
ill
effect
rvsvzebov
gp
case
remain
unclear
never
confirm
individu
actual
infect
zebov
current
postexposur
treatment
nonhuman
primat
success
marv
sebov
zebov
apart
differ
virus
develop
symptom
death
delay
marvand
sebovinfect
monkey
compar
zebov
may
one
reason
behind
greater
postexposur
efficaci
rvsvmarv
gp
sebov
gp
vaccin
interest
determin
whether
rvsv
also
efficaci
postexposur
heterolog
marv
strain
notabl
angola
result
time
death
similar
zebov
ebov
marv
infect
appear
progress
somewhat
slower
human
nonhuman
primat
would
suggest
therapeut
window
postexposur
treatment
human
may
longer
furthermor
challeng
dose
use
rvsv
trial
repres
approxim
lethal
dose
ld
almost
circumst
higher
would
expect
laboratori
direct
contact
exposur
futur
studi
interest
see
blend
vaccin
similar
use
prophylact
protect
abil
also
work
postexposur
similar
prophylact
vaccin
correl
protect
postexposur
treatment
also
unclear
indic
surviv
includ
abil
control
viremia
day
postinfect
current
specul
suggest
rapid
develop
nonneutr
antibodi
increas
nk
cell
correl
surviv
follow
postexposur
treatment
nk
cell
also
associ
protect
vlp
platform
anoth
hypothesi
rvsv
vaccin
vector
infect
target
cell
filovirus
outcompet
wildtyp
infect
therebi
inhibit
filoviru
replic
viral
interfer
altern
vsv
may
induc
innat
immun
respons
suffici
overcom
challeng
viru
infect
human
parainfluenza
viru
member
paramyxovirida
famili
common
pediatr
respiratori
viru
modifi
express
zebov
gp
addit
protein
gp
liveattenu
also
investig
pediatr
vaccin
dual
vaccin
vector
measl
gp
caus
obviou
diseas
guinea
pig
rhesu
macaqu
administ
intranas
intratrach
rout
singl
intranas
intratrach
dose
either
gp
gpnucleoprotein
np
suffici
protect
guinea
pig
zebov
challeng
rhesu
macaqu
singl
intranas
dose
induc
moder
immun
respons
protect
anim
zebov
challeng
although
show
sign
diseas
improv
surviv
two
intranas
immun
induc
stronger
immun
respons
prevent
sign
diseas
sinc
nearli
adult
immun
preexist
immun
may
interfer
vaccin
guinea
pig
despit
restrict
gp
replic
neutral
antibodi
anim
produc
zebov
gpspecif
antibodi
nearli
level
anim
rhesu
macaqu
antibodi
respons
zebov
gp
substanti
lower
compar
anim
follow
first
immun
howev
antibodi
respons
compar
immun
anim
follow
second
immun
achiev
level
previous
character
requir
protect
model
unfortun
report
anim
challeng
demonstr
preexist
immun
interfer
protect
challeng
order
circumv
preexist
vector
immun
construct
contain
f
hn
gene
develop
sole
express
zebov
gp
surfac
replic
guinea
pig
lung
appear
even
restrict
singl
immun
suffici
protect
guinea
pig
lethal
zebov
challeng
induc
immun
respons
compar
previou
construct
construct
abl
incorpor
twofold
zebov
gp
viru
particl
also
appear
even
attenu
complet
vector
use
previou
experi
date
report
util
construct
macaqu
model
initi
result
encourag
develop
platform
requir
demonstr
preexist
immun
overcom
macaqu
model
determinin
whether
crossprotect
ebov
speci
develop
marv
gpexpress
construct
requir
intranas
deliveri
elimin
need
needl
restrict
vector
replic
respiratori
tract
thought
add
safeti
similar
vaccin
igg
respons
appear
correl
immun
howev
cellular
immun
respons
vector
describ
platform
appear
induc
system
local
immun
respons
possibl
iga
respons
lung
may
advantag
aerosol
infect
rout
product
straightforward
perform
approv
cell
line
vaccin
candid
nonrepl
gener
consid
safer
live
vector
vaccin
abil
replic
condit
eg
compromis
immun
system
case
concurr
infect
anoth
pathogen
tradeoff
potenti
enhanc
safeti
higher
dose
vaccin
multipl
immun
less
robust
shorterdur
immun
case
eg
adenoviru
preexist
immun
vector
addit
obstacl
filovirus
number
effect
nonrepl
vaccin
develop
includ
venezuelan
equin
enceph
viru
replicon
veer
dna
adenoviru
rad
serotyp
combin
vlp
ebov
construct
critic
gene
delet
zebov
venezuelan
equin
enceph
viru
veev
alphaviru
genet
manipul
place
openread
frame
encod
veev
structur
protein
gene
interest
eg
zebov
gp
np
ad
result
replicon
veer
structur
gene
veev
suppli
tran
veevlik
particl
produc
capabl
carri
singlecycl
infect
thu
express
immunogen
interest
veer
express
marv
gpmusok
without
np
protect
cynomolgu
macaqu
homolog
challeng
follow
three
vaccin
howev
subsequ
experi
show
platform
provid
protect
heterolog
marvravn
challeng
veer
express
zebov
gp
without
np
shown
complet
protect
homolog
challeng
balbc
mice
cell
shown
import
protect
guinea
pig
cynomolgu
macaqu
develop
veer
platform
progress
biodefens
purpos
eg
develop
multiag
platform
util
platform
nonhuman
primat
report
dna
vaccin
novel
vaccin
platform
current
develop
multipl
pathogen
hepat
b
viru
influenza
viru
hiv
sarscoronaviru
west
nile
viru
dna
vaccin
attract
easi
produc
readili
scalabl
noninfecti
reus
preexist
immun
relev
abil
induc
humor
cellular
immun
geneticbas
vaccin
also
rapidli
alter
pathogen
evolv
cross
speci
barrier
intent
modifi
clinic
trial
dna
vaccin
appear
good
safeti
profil
howev
immunogen
less
desir
current
appear
dnabas
platform
use
standalon
vaccin
instead
part
primeboost
strategi
eg
vector
regardless
limit
immunogen
effect
dna
vaccin
alon
filovirus
investig
cynomolgu
macaqu
anim
protect
homolog
challeng
marvmusok
receiv
three
dose
dna
vaccin
contain
marvmusok
gp
surprisingli
correl
antibodi
product
protect
suggest
cellmedi
immun
may
import
howev
investig
singl
immun
optim
codonoptim
promot
modif
marvangola
gp
dna
vaccin
immunogen
evok
igg
respons
order
magnitud
less
induc
singl
immun
construct
follow
four
vaccin
dna
vaccin
abl
induc
igg
titer
compar
singl
immun
gp
regimen
abl
protect
cynomolgu
macaqu
homolog
challeng
howev
anim
show
clinic
sign
ill
lymphocyt
deplet
suggest
surviv
challeng
dna
vaccin
optim
control
marv
infect
first
clinic
trial
filoviru
vaccin
threeplasmid
dna
vaccin
use
combin
experi
describ
encod
zebov
gp
sebov
gp
zebov
np
found
safe
immunogen
phase
trial
human
three
inject
either
mg
vector
given
signific
advers
reaction
coagul
abnorm
report
individu
studi
observ
specif
antibodi
andor
tcell
respons
least
one
antigen
antibodi
titer
report
compar
nonhuman
primat
immun
similar
regimen
suggest
individu
may
surviv
ebov
infect
like
suffer
ill
first
vaccin
offer
protect
ebov
nonhuman
primat
combin
vaccin
protect
anim
zebov
challeng
dna
prime
boost
strategi
result
broad
immun
respons
includ
tand
bcell
respons
combin
strategi
result
respons
least
higher
dna
alon
three
dna
vaccin
zebov
gp
sebov
gp
ciebov
gp
zebov
np
follow
singl
zebov
gp
boost
upon
challeng
anim
develop
diseas
one
four
anim
develop
viremia
strategi
also
carri
use
marvangola
gp
comparison
either
dna
alon
far
highest
titer
obtain
combin
immun
schedul
wherebi
dnaprim
anim
boost
similar
igg
titer
highest
cellular
respons
also
observ
anim
anim
receiv
either
alon
combin
gener
predomin
respons
receiv
dna
alon
tend
favor
anim
protect
viremia
indic
success
method
vaccin
would
includ
dna
vector
multipl
speci
ebov
proven
difficult
gener
singl
vaccin
protect
speci
multival
blend
vaccin
provid
protect
multipl
speci
howev
add
addit
complex
would
necessarili
provid
protect
newli
emerg
speci
four
speci
ebov
definit
establish
new
speci
bebov
emerg
base
previou
data
blend
vaccin
rvsv
multival
vaccin
neither
platform
would
expect
protect
new
speci
howev
recent
report
vaccin
express
gp
zebov
sebov
abl
provid
protect
challeng
bebov
despit
sequenc
differ
amino
acid
level
mechan
provid
crossprotect
clear
specul
primeboost
regimen
elicit
stronger
immun
respons
one
magnitud
increas
antibodi
titer
addit
bebov
appear
less
pathogen
either
zebov
sebov
base
time
death
nonhuman
primat
casefat
rate
human
outbreak
observ
one
survivor
four
control
group
evid
igg
crossreact
bebov
therefor
despit
extrem
high
titer
antibodi
seem
mechan
protect
cell
stimul
bebov
peptid
lesser
extent
zebov
peptid
anim
lowest
stimul
show
greatest
symptom
diseas
includ
elev
liver
enzym
detect
viremia
day
suggest
cellular
respons
may
involv
crossprotect
first
descript
crossprotect
ebov
speci
system
vaccin
regimen
includ
four
dna
immun
one
boost
cours
nearli
year
unfortun
vaccin
schedul
practic
use
filovirusendem
region
vaccin
deliveri
logist
challeng
dna
boost
vaccin
regimen
proven
effect
provid
prophylact
protect
vaccin
dosag
schedul
requir
multipl
immun
month
year
time
frame
long
effect
intervent
outbreak
bioterror
event
twodos
zebov
gp
schedul
provid
surviv
viremia
detect
howev
booster
increas
antibodi
respons
presum
due
vector
immun
primari
immun
singl
immun
also
tri
singl
vaccin
particl
zebov
gp
zebov
np
also
provid
surviv
day
postvaccin
studi
determin
least
particl
zebov
gp
requir
prevent
viremia
maintain
surviv
addit
show
inclus
np
requir
panfiloviru
complex
adenoviru
cadvax
develop
four
differ
construct
deliv
two
copi
zebov
np
singl
copi
sebov
gp
zebov
gp
gp
marvravn
gp
marvmusok
gp
marvmusok
np
follow
two
immun
blend
vaccin
abl
protect
cynomolgu
macaqu
challeng
zebov
marvmusok
subsequ
backchalleng
sebov
respect
anim
show
sign
ill
alter
liver
enzym
anim
show
compar
igg
titer
five
filovirus
demonstr
singl
blendedcomplex
vaccin
provid
protect
multipl
filovirus
similarli
multival
vaccin
candid
express
zebov
gp
sebov
gp
singl
cadvax
abl
provid
protect
parenter
aerosol
challeng
sebov
requir
two
vaccin
zebov
preexist
immun
present
gener
popul
high
africa
seriou
problem
vaccin
efficaci
macaqu
immun
protect
zebov
challeng
immun
gp
overcom
differ
serotyp
adenoviru
use
chimpanzeebas
adenoviru
vaccin
express
zebov
gp
stimul
robust
tand
bcell
respons
zebov
naiv
mice
induc
complet
protect
homolog
lethal
challeng
platform
also
abl
protect
guinea
pig
challeng
rel
low
vaccin
dose
particleskg
preexist
immun
mice
affect
efficaci
vaccin
suggest
potenti
use
order
circumv
preexist
immun
similarli
chimer
simian
adenoviru
express
zebov
gp
gener
zebov
gp
describ
ad
construct
induc
zebov
gpspecif
tand
bcell
respons
lower
magnitud
compar
construct
howev
total
igg
respons
zebov
gp
compar
singl
administr
zebov
protect
mice
lethal
challeng
rhesu
macaqu
vaccin
zebov
gp
also
mount
tcell
antibodi
respons
zebov
gp
appear
success
strategi
avoid
preexist
immun
util
vector
yet
demonstr
nonhuman
primat
challeng
model
altern
mean
avoid
preexist
immun
adbas
vector
deliv
oral
nasal
vaccin
protect
lethal
challeng
zebov
mous
model
tand
bcell
respons
observ
mice
receiv
oral
nasal
vaccin
indic
qualit
improv
immun
respons
mucos
immun
compar
intramuscular
vaccin
thu
mucos
immun
result
better
stimul
cell
effector
memori
cell
intramuscular
administr
vaccin
howev
presenc
preexist
immun
mice
vaccin
intranas
rout
protect
nextgener
vector
contain
improv
express
cassett
adcagoptzgp
demonstr
higher
express
zebov
gp
significantli
improv
tand
bcell
respons
dose
ten
lower
requir
adcmvzgp
previou
vaccin
base
addit
vector
provid
protect
lethal
challeng
mice
dose
lower
previou
vector
surprisingli
abl
protect
mice
given
min
postchalleng
suggest
radbas
vector
may
also
abil
provid
protect
postexposur
data
interest
must
demonstr
nonhuman
primat
model
proven
difficult
protect
postexposur
compar
either
mous
guinea
pig
model
viruslik
particl
success
develop
wide
avail
commerci
vaccin
hepat
b
viru
hpv
vaccin
proven
highli
efficaci
excel
safeti
record
vlp
lack
viral
genet
materi
consid
noninfecti
thu
safer
replic
vaccin
also
like
vlp
interact
target
cell
actual
viru
administ
multipl
time
increas
immun
respons
present
viru
glycoprotein
nativ
state
ebov
marv
express
structur
protein
matrix
protein
gp
result
format
vlp
similar
morpholog
virion
alon
suffici
drive
vlp
format
bud
process
enhanc
presenc
gp
np
moreov
protect
mediat
gp
zair
ebolaviru
marv
vlp
demonstr
provid
protect
homolog
zebov
marv
challeng
mice
guinea
pig
respect
seen
vaccin
platform
crossprotect
filoviru
speci
effort
develop
panfiloviru
vaccin
hybrid
vlp
incorpor
zebov
marv
gp
either
marv
zebov
gener
hybrid
vlp
effect
protect
heterolog
challeng
howev
blend
vaccin
ribi
adjuv
contain
zebov
marv
vlp
provid
high
level
protect
challeng
either
zebov
surviv
marv
surviv
guinea
pig
efficaci
vlp
nonhuman
primat
demonstr
marv
zebov
cynomolgu
macaqu
immun
three
dose
zebov
vlp
contain
gp
np
ribi
adjuv
result
surviv
anim
without
sign
ill
viremia
marvmusok
gp
np
vlp
adjuv
shown
provid
protect
challeng
marv
strain
includ
angola
ravn
cynomolgu
macaqu
howev
anim
challeng
ravn
show
sign
ill
product
vlp
mammalian
cell
expens
therefor
altern
product
method
investig
zebov
vlp
produc
insect
cell
via
baculoviru
express
shown
compar
immunogen
mammalianproduc
vlp
follow
two
immun
insect
cellderiv
vlp
protect
mice
zebov
challeng
revers
genet
use
replac
essenti
transcript
factor
zebov
genom
report
gene
neomycin
gener
ebola
replic
viru
restrict
cell
express
tran
ie
stabl
cell
line
ebola
produc
cell
appear
ident
morpholog
wildtyp
viru
similar
growth
kinet
demonstr
genet
stabl
multipl
seven
passag
suggest
recombin
wherebi
could
reintroduc
ebov
genom
unlik
infect
cell
express
tran
demonstr
replic
ebola
restrict
cell
evalu
safeti
deliveri
ebola
alon
cell
mice
perform
show
neither
caus
sign
ill
diseas
highli
suscept
anim
model
recombin
like
mice
vaccin
viru
develop
detect
igg
antibodi
respons
follow
first
vaccin
subsequ
increas
second
third
boost
increas
tcell
respons
also
note
follow
two
immun
mice
immun
twice
ebola
surviv
subsequ
challeng
mouseadapt
zebov
show
evid
ill
viremia
vaccin
mice
significantli
lower
nonvaccin
mice
guinea
pig
vaccin
twice
ebola
also
surviv
challeng
guinea
pigadapt
zebov
also
show
sign
ill
vaccin
platform
yet
evalu
nonhuman
primat
current
data
would
suggest
proven
safe
effect
vaccin
mice
guinea
pig
benefit
deliv
viral
protein
may
prove
use
crossprotect
ebov
speci
although
remain
determin
regardless
perceiv
safeti
risk
six
seven
gene
remain
construct
may
limit
potenti
develop
lack
welldefin
popul
target
filoviru
vaccin
campaign
highrisk
group
specif
popul
equatori
africa
would
probabl
target
vaccin
current
demonstr
need
wider
coverag
marv
outbreak
tempor
geograph
sporad
determin
region
prophylact
vaccin
extrem
difficult
ebov
endem
area
ie
eastern
gabon
western
republ
congo
larg
portion
democrat
republ
congo
part
uganda
widespread
vaccin
campaign
could
consid
includ
protect
marv
popul
without
merit
overlap
virus
region
human
marv
infect
associ
visit
cave
around
mount
elgon
near
kenyasudan
border
appropri
educ
precaut
consid
time
rather
vaccin
intern
aid
worker
work
endem
region
respond
diseas
outbreak
equatori
africa
would
also
benefit
prophylact
vaccin
prioriti
popul
would
laboratori
worker
handl
agent
addit
popul
may
benefit
prophylact
vaccin
would
includ
first
respond
frontlin
hospit
staff
militari
personnel
prophylact
vaccin
desir
logist
ensur
good
vaccin
coverag
equatori
africa
difficult
make
rapidact
andor
postexposur
vaccin
desir
would
potenti
decreas
casefat
rate
prevent
spread
diseas
outbreak
would
also
use
strategi
minim
fatal
follow
bioterror
event
multipl
vaccin
platform
summar
tabl
proven
efficaci
prevent
vaccin
nonhuman
primat
model
filoviru
infect
detail
progress
current
avail
rvsv
vaccin
platform
dna
vaccin
alon
test
phase
clinic
trial
immunogen
less
desir
requir
multipl
immun
long
time
period
requir
multipl
immun
make
platform
difficult
implement
filovirusendem
region
vaccin
entir
popul
probabl
logist
financi
imposs
howev
may
use
vaccin
individu
high
potenti
exposur
risk
eg
biosafeti
worker
frontlin
hospit
stafffirst
respond
member
agenc
work
endem
area
group
use
target
vaccin
atrisk
popul
would
unlik
benefit
vaccin
addit
primeboost
regimen
alon
probabl
util
howev
method
overcom
preexist
immun
definit
proven
nonhuman
primat
model
multipl
option
avoid
circumv
preexist
immun
still
use
ad
vector
present
although
none
method
thoroughli
test
nonhuman
primat
challeng
model
owe
amount
data
avail
nonhuman
primat
studi
limit
clinic
trial
combin
vaccin
platform
like
progress
fastest
clinic
trial
concern
safeti
continu
delay
use
rvsv
vaccin
platform
despit
convinc
evid
safeti
nonhuman
primat
model
includ
immunocompromis
shiv
model
rvsv
continu
vaccin
platform
potenti
prevent
diseas
death
postexposur
chosen
treatment
follow
recent
laboratori
exposur
demonstr
effect
follow
singl
dose
signific
advantag
provid
vaccin
target
popul
central
africa
furthermor
vaccin
work
preand
postexposur
rel
short
time
immun
could
store
requir
ie
laboratori
exposur
bioterror
outbreak
rapidli
implement
need
probabl
repres
costeffect
approach
could
possibl
circumv
need
full
regulatori
approv
vaccin
could
ad
new
investig
drug
list
rapid
use
event
emerg
vaccin
platform
appear
promis
accumul
great
quantiti
data
two
lead
platform
appear
potenti
prevent
vaccin
howev
crossprotect
studi
develop
vaccin
anyth
zebov
report
nonhuman
primat
studi
use
construct
complet
avoid
preexist
immun
dictat
futur
success
platform
vlp
also
promis
prevent
vaccin
howev
requir
multipl
immun
expect
high
product
cost
may
limit
use
target
popul
eg
central
africa
furthermor
gener
vlp
vaccin
ebov
speci
yet
demonstr
abil
combin
vlp
technic
possibl
may
increas
cost
platform
final
zebov
vaccin
yet
proven
nonhuman
primat
current
avail
zebov
thu
limit
amount
data
uncertainti
safeti
vaccin
preclud
detail
evalu
potenti
futur
clinic
use
multipl
option
current
avail
could
probabl
develop
success
vaccin
ebov
marv
unfortun
lesson
learn
past
discourag
absenc
precipit
factor
laboratori
exposur
diseas
outbreak
western
world
develop
prevent
andor
postexposur
vaccin
like
slow
limit
interest
industri
given
lack
profit
vaccin
anoth
inhibit
factor
thu
govern
agenc
need
provid
fund
vaccin
develop
field
immin
use
obviou
high
contain
field
anxious
await
treatment
andor
vaccin
option
worker
therefor
preinvestig
new
drug
ind
approv
consid
promis
platform
howev
would
trigger
request
aid
agenc
militari
alreadi
indic
interest
protect
staff
avail
preind
approv
vaccin
would
also
probabl
creat
ethic
dilemma
govern
healthcar
provid
popul
affect
endem
central
african
countri
need
vaccin
treatment
option
absenc
welldefin
correl
protect
establish
clinic
trial
meet
current
standard
difficult
area
probabl
controversi
overal
mean
avail
filoviru
vaccin
probabl
remain
unrealist
within
next
year
step
right
direct
might
preind
approv
candid
vaccin
emerg
use
hope
pave
way
develop
futur
licens
vaccin
filovirus
caus
unpredict
sporad
outbreak
high
casefat
rate
equatori
africa
potenti
use
bioterror
result
continu
potenti
caus
laboratori
fatal
follow
accident
exposur
approv
option
intervent
make
develop
prophylact
therapeut
vaccin
desir
number
platform
proven
success
prophylact
vaccin
recombin
vesicular
stomat
viru
dnarecombin
adenoviru
viruslik
particl
recombin
human
parainfluenza
viru
dna
platform
proceed
phase
clinic
trial
clinic
trial
ebola
marburg
virus
complic
low
frequenc
geograph
unpredict
outbreak
lack
correl
protect
inabl
test
vaccin
efficaci
challeng
sever
vaccin
approach
consid
distinct
applic
best
address
contraind
associ
certain
platform
postexposur
treatment
vaccin
appear
effici
econom
mean
control
outbreak
respond
bioterror
event
propos
reservoir
ebola
marburg
virus
number
speci
african
fruit
bat
multipl
outbreak
associ
locat
contact
consumpt
bat
occur
contact
infect
nonhuman
primat
typic
bush
meat
also
suspect
sourc
infect
mechan
transmiss
bat
human
nonhuman
primat
known
transmiss
nonhuman
primat
human
like
contact
blood
tissu
butcher
bite
scratch
transmiss
human
probabl
occur
via
direct
contact
blood
secret
howev
limit
evid
aerosol
transmiss
event
act
bioterror
like
rout
infect
would
aerosol
rout
